shutterstock_138095450

Grünenthal buys European rights to AstraZeneca’s Crestor for a potential $350m

pharmafile | December 1, 2020 | News story | Manufacturing and Production, Sales and Marketing AstraZeneca, Crestor, Grunenthal 

Grünenthal has picked up AstraZeneca’s statin therapy Crestor (rosuvastatin), currently approved in dyslipidaemia and hypercholesterolaemia treatment, in a deal worth a possible $350 million.

The deal awards Grünenthal the rights to market the Crestor in more than 30 European countries in Europe; however, the UK and Spain are excluded from the deal. In the same countries covered under the agreement, the drug generated sales of $136 million with a profit before tax of $98 million in 2019.

Upon closing of the deal expected in the first quarter of next year, Grünenthal will make an upfront payment of $320 million to AZ, with further milestone payments of up to $30 million to potentially follow.

“This agreement supports the management of our mature medicines to enable reinvestment into the pipeline and bringing new, innovative treatments to patients,” commented Ruud Dobber, Executive Vice President at AZ’s BioPharmaceuticals Business Unit. Grünenthal previously acquired the rights to several established AstraZeneca medicines and is well placed to ensure continued access to Crestor for patients across Europe.”

Advertisement

AZ confirmed that it will retain the rights to the medicine in the US, Japan, China and others not covered in the deal, and will continue to handle manufacturing to supply Grünenthal with the drug during the transition period.

Matt Fellows

Related Content

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

Astra Zeneca Logo

Purpose and people: the enduring power of brand and the evolution of employer identity

Two decades ago, terms like purpose and people were rarely at the forefront of branding …

The Gateway to Local Adoption Series

Latest content